Hospira Recalls Propofol Injectable Emulsion, USP

Lake Forest, Ill.-based Hospira has voluntarily recalled seven lots of its Propofol Injectable Emulsion, USP, citing metal particulate embedded in the interior neck of the vial as well as free-floating metal particulates found in the vials.

Advertisement

Hospira has not received any reports of adverse events associated with these lots. However, if injected, the particulate matter could lead to local inflammation or obstructed capillaries.

More Articles on Recalls:

What the Increase in Device Recalls Means for Hospitals
Covidien Recalls Pipeline Embolization Device, Alligator Retrieval Device
Dräger Recalls Ventilator Power Supply Unit for Evita, Babylog Ventilators

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Rethinking Safety and Security in the Healthcare Environment

Thursday, July 23
1:00 PM - 2:00 PM CDT

Presenters: Jon Share, AxonDan Snyder, Advocate HealthKeith Hunter, Wellstar

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.